MELBOURNE, Australia — Two-year data from the SELECT-GCA trial of the JAK inhibitor upadacitinib in patients with giant cell arteritis (GCA) suggest the drug can maintain remission for the longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results